Targeting cancer using genetically modified high affinity T-cell receptors
Cardiff Institute of Infection & Immunity
A three-year project using enhanced T-cell receptors to target cancer. Initial results indicate that we manufacture T-cells that are better at killing cancer cells than anything the body can produce naturally.
Award
This Tenovus foundation studentship is for 3 years and pays a stipend and all registration fees.
The studentship will not pay international fees so this award is only open to nationals of the European Union.
Research focus
This project will involve using enhanced T-cell receptors to target cancer. Initial results are extremely promising and indicate that we manufacture T-cells that are >100X better at killing cancer cells than anything the body can produce naturally.
We are also working with Immunocore LTD to use soluble high affinity TCRs to eradicate cancer cells. This project is expected to produce extremely significant results. Relevant Clinical Trials are planned to take place at the University of Pennsylvania.
- Please contact
- Dr Nathan Bromham
- Closing date for applications
- 1st March 2010